Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Daniel C. Mendez"'
Autor:
Kristin M. Snyder, Robert Hullsiek, Hemant K. Mishra, Daniel C. Mendez, Yunfang Li, Allison Rogich, Dan S. Kaufman, Jianming Wu, Bruce Walcheck
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Anti-tumor mAbs are the most widely used and characterized cancer immunotherapy. Despite having a significant impact on some malignancies, most cancer patients respond poorly or develop resistance to this therapy. A known mechanism of action of these
Externí odkaz:
https://doaj.org/article/bc54b2b1b11846429fb2a538039cd069
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 6688, p 6688 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Sepsis is the culmination of hyperinflammation and immune suppression in response to severe infection. Neutrophils are critical early responders to bacterial infection but can become highly dysfunctional during sepsis and other inflammatory disorders
Autor:
Kristin M Snyder, Robert Hullsiek, Hemant Kumar Mishra, Kate J Dixon, Daniel C Mendez, Yunfang Li, Allison Rogich, Jianming Wu, Bruce Walcheck
Publikováno v:
The Journal of Immunology. 204:239.26-239.26
Natural killer (NK) cells are cytotoxic lymphocytes that can rapidly kill tumor cells with exquisite specificity by antibody-dependent cell-mediated cytotoxicity (ADCC), which is exclusively mediated by the IgG Fcγ receptor CD16A. Many clinically su
Autor:
Jianming Wu, Bruce Walcheck, Hemant K. Mishra, Daniel C. Mendez, Dan S. Kaufman, Robert Hullsiek, Yunfang Li, Allison Rogich, Kristin M. Snyder
Publikováno v:
Snyder, Kristin M; Hullsiek, Robert; Mishra, Hemant K; Mendez, Daniel C; Li, Yunfang; Rogich, Allison; et al.(2018). Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.. Frontiers in immunology, 9, 2873. doi: 10.3389/fimmu.2018.02873. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/0zk7b21q
Frontiers in Immunology
Frontiers in Immunology, Vol 9 (2018)
Frontiers in Immunology
Frontiers in Immunology, Vol 9 (2018)
Anti-tumor mAbs are the most widely used and characterized cancer immunotherapy agents. Despite having a significant impact on some malignancies, most cancer patients respond poorly or develop resistance to this therapy. A known mechanism of action o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b439e0c5f180b85ff52ed225e283527a
http://www.escholarship.org/uc/item/0zk7b21q
http://www.escholarship.org/uc/item/0zk7b21q
Autor:
Anthony D. Rangel, Alexander E. Stover, Daniel C. Mendez, Philip H. Schwartz, Omar Khalid, Patricia I. Dickson, Steven Q. Le, Shih-hsin Kan
Publikováno v:
Molecular Therapy. 23
Mucopolysaccharidosis type I (MPS I) is an inherited α-L-iduronidase (IDUA, I) deficiency in which glycosaminoglycan (GAG) accumulation causes progressive multi-system organ dysfunction, neurological impairment, and death. We developed a new MPS I m
Autor:
Daniel C. Mendez, Philip H. Schwartz, Patricia I. Dickson, Alexander E. Stover, Cian McGuire, Andrew Wong, James V. Jester, Anthony D. Rangel, Marissa A. Torres, Hubert E. Nethercott, Steven Q. Le, Jonathan D. Cooper, Shih hsin Kan, Edwin S. Monuki, David J. Brick, Omar Khalid
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 2, Iss, Pp-(2015)
Mendez, D C, Stover, A E, Rangel, A D, Brick, D J, Nethercott, H E, Torres, M A, Khalid, O, Wong, A MS, Cooper, J D, Jester, J V, Monuki, E S, McGuire, C, Le, S Q, Kan, S H, Dickson, P I & Schwartz, P H 2016, ' A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I ', Molecular Therapy-Methods and Clinical Development, vol. 2, pp. 14068 . https://doi.org/10.1038/mtm.2014.68
Molecular Therapy. Methods & Clinical Development
Mendez, DC; Stover, AE; Rangel, AD; Brick, DJ; Nethercott, HE; Torres, MA; et al.(2015). A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2, 14068. doi: 10.1038/mtm.2014.68. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/72b3586j
Mendez, D C, Stover, A E, Rangel, A D, Brick, D J, Nethercott, H E, Torres, M A, Khalid, O, Wong, A MS, Cooper, J D, Jester, J V, Monuki, E S, McGuire, C, Le, S Q, Kan, S H, Dickson, P I & Schwartz, P H 2016, ' A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I ', Molecular Therapy-Methods and Clinical Development, vol. 2, pp. 14068 . https://doi.org/10.1038/mtm.2014.68
Molecular Therapy. Methods & Clinical Development
Mendez, DC; Stover, AE; Rangel, AD; Brick, DJ; Nethercott, HE; Torres, MA; et al.(2015). A novel, long-lived, and highly engraftable immunodeficient mouse model of mucopolysaccharidosis type I. MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2, 14068. doi: 10.1038/mtm.2014.68. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/72b3586j
Mucopolysaccharidosis type I (MPS I) is an inherited α-L-iduronidase (IDUA, I) deficiency in which glycosaminoglycan (GAG) accumulation causes progressive multisystem organ dysfunction, neurological impairment, and death. Current MPS I mouse models,
Autor:
Leslie A Kirby, Jason T Schott, Brenda L Noble, Daniel C Mendez, Paul S Caseley, Sarah C Peterson, Tyler J Routledge, Nilay V Patel
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39329 (2012)
Canonical Wnt/β-catenin signaling has been suggested to promote self-renewal of pluripotent mouse and human embryonic stem cells. Here, we show that SB-216763, a glycogen synthase kinase-3 (GSK3) inhibitor, can maintain mouse embryonic stem cells (m
Externí odkaz:
https://doaj.org/article/d28c02334bc04b5f949eb4367e1f0a2f